GlassScriptPhysician profile
Ziad A Tannous
NPI 1235160003
$15,590.27
in general payments reported to CMS, 2019-2025
46 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,925 · 2020: $502 · 2021: $515 · 2022: $722 · 2023: $4,269 · 2024: $534 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,146 · Travel and Lodging: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,145.76 |
| Travel and Lodging | $781.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,079.26 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Uk Limited | $3,314.36 | 2019 | |
| Covidien LP | $1,768.98 | 2019 | |
| Olympus Corporation of The Americas | $941.02 | 2019 | |
| Glaxosmithkline, LLC. | $797.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $794.44 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.64 | 2019-2025 | Jascayd, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $536.54 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $524.84 | 2019-2025 | Airsupra, Imfinzi |
| Genentech USA, INC. | $356.44 | 2019 | |
| Viatris Specialty LLC | $173.23 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $158.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.24 | 2019 | |
| Inari Medical, INC. | $139.45 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sunovion Pharmaceuticals INC. | $122.42 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $120.73 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Electromed, INC. | $108.08 | 2019-2025 | Smartvest |
| Philips North America LLC | $96.17 | 2019-2022 | |
| Advanced Respiratory, INC | $85.42 | 2019-2020 | |
| Pfizer INC. | $69.21 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.47 | 2020-2022 | |
| United Therapeutics Corporation | $64.03 | 2025 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $51.29 | 2019 | |
| Erbe USA INC | $50.00 | 2024 | |
| Baxter Healthcare | $48.61 | 2025 | Hillrom - Volara System |
| Genzyme Corporation | $46.14 | 2021-2025 | |
| Grifols USA, LLC | $42.82 | 2020-2024 | Prolastin-C Liquid |
| Janssen Biotech, INC. | $31.11 | 2024 | Darzalex, Tecvayli, Talvey |
| Regeneron Healthcare Solutions, INC. | $30.12 | 2025 | Libtayo |
| Incyte Corporation | $25.96 | 2025 | Jakafi |
| Astellas Pharma US INC | $25.06 | 2025 | Xtandi |
| Gilead Sciences, INC. | $23.33 | 2021 | |
| Getinge USA Sales, LLC | $22.31 | 2022 | |
| Verona Pharma, INC. | $22.05 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $20.26 | 2019 | |
| Circassia INC. | $19.99 | 2019 | |
| Pulmonx Corporation | $18.35 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.95 | 2019 | |
| Ambu INC. | $14.56 | 2020 | |
| Olympus America INC. | $12.11 | 2022 | |
| Veran Medical Technologies, INC. | $11.57 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Tannous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.